🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

TCRT TCRT

Company Profile ↓
$2.02
-26.28% 1Y
Mkt Cap$4.75M
P/E-0.92
P/B2.20
52W High$4.36
52W Low$1.77
Book Value$0.92
EPS (TTM)$-2.20

Company Overview

TCRT (TCRT) is a publicly traded company listed on with a market capitalization of $4.75M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

  • Dec 2025 Revenue of $5.00K (-50.0% YoY); net profit $-4.18M.
  • Trailing 12 Months Year-on-year growth — revenue -50.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -41.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-41.94%
1 Year:-50.00%

Stock Price Performance

1 Year:-26.28%
6 Months:-21.71%
3 Months:-22.61%
1 Month:-0.98%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 10% of range
$1.77 $4.36
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)49.31 · Neutral
Price Performance
1M-0.98%
3M-22.61%
6M-21.71%
1Y-26.28%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -41.9% CAGR over 5 years.
  • Trading 53.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.92
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$0.92
Price to Book
2.20
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-41.94%
Profit 5Y
-
Revenue (YoY)
-50.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.59
EPS (TTM)
$-2.20

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
-
Current Ratio
2.45
Debt
$0
Total Assets
$1.88M
Current Assets
$970.00K
Working Capital
$1.18M

Ownership

Promoter Holding
15.73%
Chg in Prom Hold
-
FII / Inst Holding
6.53%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$5.00K
EBITDA
$-4.22M
Free Cash Flow
$-2.97M
Operating Cash Flow
$-2.87M
Shares Outstanding
2.35M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------1.60M1.60M1.60M1.60M146.00K000----0000--398.00K-02.91M04.00K01.00K4.00K0-2.00K003.00K0
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------1.09M1.04M1.19M910.00K1.01M
Operating Income -18.17M-9.48M-12.04M-131.24M-10.91M-11.11M-13.96M-13.01M-13.08M-13.44M-16.20M-12.38M-12.57M-12.76M-13.62M-14.75M-13.45M-16.04M-18.66M-18.61M-20.32M-22.77M-21.56M-22.64M-22.30M-9.09M-9.23M-8.26M-9.67M-7.98M-8.66M-1.74M-1.17M-1.15M--1.09M-1.04M-1.19M-907.00K-1.01M
EBITDA ------------------------------------1.09M-1.04M-1.19M-900.00K-1.00M
Interest Expense ----------------------------------0-----
Pretax Income ------------------------------------1.07M-1.05M-1.16M-893.00K-1.01M
Tax Provision ----------------------------------------
Net Income -18.17M-9.48M-12.02M-131.20M-14.45M-14.76M-19.66M-17.73M-17.60M-18.27M-21.14M-17.49M-18.66M194.54M-13.43M-14.62M-74.00M-15.75M-18.29M-18.60M-20.32M-22.77M-21.55M-22.67M-22.73M-9.79M-9.93M-8.85M-10.05M-8.77M-8.48M-1.68M-1.13M-1.13M--1.07M-1.05M-1.16M-893.00K-1.01M
Diluted EPS -----------0.15-0.12-0.131.29-0.08-0.09-0.43-0.09-0.09-0.09-0.10-0.11--0.11-0.11-0.05-0.05-0.04-0.63-5.49-5.30-1.05-0.71-0.70--0.67-0.63-0.55--0.59
R&D Expense 16.97M-10.20M129.23M8.97M-11.97M10.83M11.11M-10.18M7.49M8.26M-9.48M10.00M8.64M-12.71M12.05M13.97M-13.34M13.57M14.52M5.58M5.94M7.89M6.50M5.19M3.66M126.00K180.00K143.00K-347.00K185.00K469.00K-427.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------667.00K800.00K---6.86M6.39M146.00K-0-2.92M5.00K10.00K5.00K
Cost of Revenue ----------------------
Gross Profit ----------------------
Operating Expenses ------------------38.16M28.50M4.82M4.23M
Operating Income ------12.12M-24.55M-71.40M-102.17M-57.71M-43.50M-120.10M-165.31M-53.49M-53.91M-57.86M-80.36M--35.24M-28.49M-4.81M-4.22M
EBITDA -------------------31.82M-30.90M-4.81M-4.22M
Interest Expense -----------------1.19M3.15M1.92M0-
Pretax Income -------------------37.73M-35.14M-4.68M-4.18M
Tax Provision ----------------------
Net Income -5.69M-9.52M-17.86M-26.61M-25.23M-7.65M-32.67M-63.78M-96.13M-57.11M-31.78M-120.09M-165.30M-54.32M-53.12M-117.80M-79.98M--37.73M-35.14M-4.68M-4.18M
Diluted EPS -------------1.32-0.530.96-0.70-0.38--25.50-21.97-2.92-2.20
R&D Expense -----4.56M12.91M57.08M83.45M42.85M32.71M106.78M157.79M45.08M34.13M38.33M52.70M49.64M25.02M16.28M362.00K1.36M

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2003Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --------61.52M108.11M83.40M71.75M45.24M153.72M106.35M105.61M95.05M109.11M146.34M-64.94M8.26M2.75M2.97M
Current Assets --------------------53.80M8.26M2.75M1.99M
Cash & Equivalents 0-----11.38M48.84M60.39M104.71M73.31M68.20M42.80M140.72M81.05M70.95M61.73M79.74M115.07M-39.06M6.06M1.09M1.39M
Inventory ------------------------
Receivables --------------------4.00K1.00K5.00K3.00K
Total Liabilities --------30.97M36.50M34.96M22.37M11.40M66.35M58.33M58.42M9.49M14.10M22.36M-26.38M1.96M692.00K813.00K
Current Liabilities --------3.61M13.36M18.86M7.79M10.83M18.12M15.81M20.86M9.48M12.53M18.37M-24.17M1.96M692.00K813.00K
Long Term Debt ------------------016.25M----
Total Debt -------------------29.36M19.51M0--
Total Equity 500.00K340.00K-144.00K7.20M26.53M30.37M6.74M28.10M30.55M71.61M48.45M49.38M33.84M87.37M-77.30M-96.81M85.56M95.01M123.98M-38.55M6.31M2.06M2.15M
Shares Outstanding --------------------1.60M1.60M1.60M2.35M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -12.29M-19.69M-38.84M-78.83M-59.51M---58.33M-54.67M-49.46M-40.85M-57.01M--29.23M-30.14M-4.97M-2.87M
Investing Cash Flow -11.00K-186.00K-1.16M-1.56M-131.00K---551.00K-737.00K-459.00K-284.00K-9.78M--193.00K1.35M0-98.00K
Financing Cash Flow 49.77M31.43M84.31M48.98M54.54M---788.00K45.30M40.31M59.15M102.12M-6.37M-18.14M03.26M
Capital Expenditure -11.00K-186.00K-1.16M-1.56M-132.00K-193.00K-412.00K-551.00K-737.00K-459.00K-284.00K-9.78M-3.32M-216.00K-197.00K--98.00K
Free Cash Flow -12.30M-19.88M-39.99M-80.39M-59.64M---58.88M-55.41M-49.92M-41.14M-66.79M--29.45M-30.34M-4.97M-2.97M
Net Change in Cash --------------23.06M-46.93M-4.97M294.00K
Share Buybacks 380.00K1.67M274.00K546.00K498.00K544.00K34.00K2.00K01.62M653.00K-045.00K0--

Ratios (Annual)

Figures in %.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------------
Operating Margin % --------10,704.6%-12,771.1%----2,409.4%-837.3%-36,921.9%----1,206.0%-569,860.0%-48,120.0%-84,500.0%
Net Margin % --------9,561.9%-12,016.5%----2,409.2%-850.3%-36,381.5%----1,291.2%-702,800.0%-46,790.0%-83,520.0%
ROE % 3,949.3%-132.1%-67.3%-87.6%-374.4%-27.2%-106.9%-89.1%-198.4%-115.6%-93.9%-137.4%213.8%56.1%-62.1%-124.0%-64.5%--97.9%-557.2%-226.8%-194.0%
ROCE % -------42.4%-75.4%-158.3%-90.2%-126.4%-88.6%-182.6%-63.1%-63.0%-59.9%-62.8%--86.4%-451.8%-233.3%-196.2%

Shareholding Pattern

Insiders
15.73%
Institutions
6.53%
Public Float
7.75%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TCRT

Google News Sat, 01 Aug 2026

Enterprise value to EBIT forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOeTB5RExrZjZ5Qjh3WlFzOHNpaTlVX3MyS1FIN2NZLUpsaGEyZ3BYVC11aUhqM25lSGx6blNzT1hRMlNXOUtGWkprekktNnlIQ0MxZm16Q3FlbG55WXN2N3Bkdmp4YkdTOTFESU5vOHVhaFh4S1NMVWwwODhYN3BWWE45aS1DNXBhbmJQdW…

Google News Mon, 27 Jul 2026

Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNUTBDMzlINU1XWlVEenFtX2IzNGRBWkRQNGRfWC1fdVBUd2Vfcmducmx4Q0tyTjVzWmxmbmhWeWtIRnFweUZhRUlQQk53d0xjbk5aaXlaS0JQQTdxS3F5NzNtUktHWjdXcUlIX3pPMUM1dkxSNFdZUnVZNzh6VHZnWWh4bExfUXRZcUh3aV…

Google News Sun, 26 Jul 2026

TCRT|Alaunos Therapeutics Inc|Price:1.910|Chg%:+0.005 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5JRVVjSDJWSWoxc2l0bnNsbHdvcnp3anEtWnEyWkNIdnhrazJOQjVHeXZhVWcxRXNBUUpZUloweUlQdVRQNDRMZ21FNzBmTmgzOTRVckRMMXVkY1hzSjZCTDJNejVyeFB5MXA3V253?oc=5" target="_blank">TCRT|Alaunos Therap…

Google News Mon, 27 Jul 2026

Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNdi1ILWZuWkFlVHZ4V2kzaHZUN3poeFc5OVJRbDRyQV83RnNSZzV4ZGdxNTRWeFg5SjduVVhmbE1pMDZaTldFbXhZQV9mMEk0U0FMd3U4ZWJaLWxDWUNaTEp1T3FqLTNPTC1GbndLYU9rRUEyY3I4VXJnN1lvcExFYkxrMWpkRi1ramFBY1…

Google News hu, 30 Jul 2026

Alaunos Therapeutics (TCRT) Shows Modest Decline Amid Tight Range Trading - Retail Volume - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNVWlfQzFDdGhDMi1Zd3VjSEMyc2RNanJXalVhYndYQzlPUzkxNEszNm9rdzc4RW9UWUdEX2JxVFRaZjJTR2YxQVVsbjB1RlAtcWNwcE9XZ0wwNG9JMDBXMkpFOE9lX2RTdFBWekkwbG5JVTNLYklybDZoMWNxemZMMzVUbTVsY2NVYXJuSG…

Google News Sat, 25 Jul 2026

Alaunos Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRT - TradingView

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9uZG5lUE1sMnoyY1FSWGs0Rm8xY3k2UnlKNjFqY2JYQmRPeGtQbDhPcUo3Vm45UGhnNVA5X3dBb2hoSnBGRDVkWk1SLWdlS2l5dWQwclo3VlEwUjROUm5GcWFFbWRqZUFpcTZKaHBsYktmSTVwcnBr?oc=5" target="_blank">Alaunos…

TCRT — Frequently Asked Questions

What is the current share price of TCRT?

As of 2026-08-05 17:25 PDT, TCRT trades at $2.02 on NASDAQ/NYSE. Its 52-week range is $1.77 to $4.36.

What is the market capitalisation of TCRT?

TCRT has a market capitalisation of $4.75M on NASDAQ/NYSE.

What is the P/E ratio of TCRT?

TCRT trades at a trailing price-to-earnings (P/E) ratio of -0.92. Its price-to-book (P/B) ratio is 2.20.

Is TCRT a good stock to buy?

This page provides a data-driven analysis of TCRT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space